tetano
Editor, Senior Moderator
Immunol Med
. 2022 May 1;1-13.
doi: 10.1080/25785826.2022.2068331. Online ahead of print.
Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review
Neelam Asghar[SUP] 1 [/SUP], Hassan Mumtaz[SUP] 2 3 [/SUP], Abdul Ahad Syed[SUP] 4 [/SUP], Farea Eqbal[SUP] 4 [/SUP], Reeju Maharjan[SUP] 5 [/SUP], Aditya Bamboria[SUP] 5 [/SUP], Manish Shrehta[SUP] 5 [/SUP]
Affiliations
Abstract
The World Health Organization stated on 11 March 2020 that a coronavirus illness had been discovered in Wuhan, China in December 2019. Effective vaccinations are eagerly awaited as the global outbreak of COVID-19 continues. The aim is to evaluate the safety, effectiveness, and immunogenicity of Pfizer/AstraZeneca/Modera/Cansino vaccines against COVID-19. An electronic search on different databases yielded 12,907 articles. A total of 20 randomized and non-randomized, published, and ongoing trials were selected. Cochrane RoB version 2.0 was used to assess the authenticity of the studies. Of these 20 trials, three were conducted on Pfizer, three on AstraZeneca, three on Moderna, and two on the Cansino vaccine. These trials have reported promising results for the safety, efficacy, and immunogenicity of the respective vaccines. None of the trials have reported the efficacy and severe adverse outcomes for the Cansino vaccine, hindering its reliability as a safe vaccine against covid-19. Furthermore, the results of these trials have established Pfizer to be the most efficacious vaccine against covid-19, having an efficacy of 94.6%. A few severe adverse events were reported by the included trials. However, further systematic reviews are required to understand the respective vaccine profiles on Immuno-suppressive, organ transplants, and patients with other comorbidities.
Keywords: Covid-19; efficacy; immunogenicity; safety; vaccines.
. 2022 May 1;1-13.
doi: 10.1080/25785826.2022.2068331. Online ahead of print.
Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review
Neelam Asghar[SUP] 1 [/SUP], Hassan Mumtaz[SUP] 2 3 [/SUP], Abdul Ahad Syed[SUP] 4 [/SUP], Farea Eqbal[SUP] 4 [/SUP], Reeju Maharjan[SUP] 5 [/SUP], Aditya Bamboria[SUP] 5 [/SUP], Manish Shrehta[SUP] 5 [/SUP]
Affiliations
- PMID: 35491898
- DOI: 10.1080/25785826.2022.2068331
Abstract
The World Health Organization stated on 11 March 2020 that a coronavirus illness had been discovered in Wuhan, China in December 2019. Effective vaccinations are eagerly awaited as the global outbreak of COVID-19 continues. The aim is to evaluate the safety, effectiveness, and immunogenicity of Pfizer/AstraZeneca/Modera/Cansino vaccines against COVID-19. An electronic search on different databases yielded 12,907 articles. A total of 20 randomized and non-randomized, published, and ongoing trials were selected. Cochrane RoB version 2.0 was used to assess the authenticity of the studies. Of these 20 trials, three were conducted on Pfizer, three on AstraZeneca, three on Moderna, and two on the Cansino vaccine. These trials have reported promising results for the safety, efficacy, and immunogenicity of the respective vaccines. None of the trials have reported the efficacy and severe adverse outcomes for the Cansino vaccine, hindering its reliability as a safe vaccine against covid-19. Furthermore, the results of these trials have established Pfizer to be the most efficacious vaccine against covid-19, having an efficacy of 94.6%. A few severe adverse events were reported by the included trials. However, further systematic reviews are required to understand the respective vaccine profiles on Immuno-suppressive, organ transplants, and patients with other comorbidities.
Keywords: Covid-19; efficacy; immunogenicity; safety; vaccines.